Sarepta Therapeutics, Inc. (SRPT)

NASDAQ: SRPT · Real-Time Price · USD

17.79

+0.96 (5.70%)

At close: Oct 15, 2026, 4:00 PM EDT

17.79

0.00 (0.00%)

After-hours: Oct 15, 2026, 4:27 PM EDT

Sarepta Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,974	2,198	1,902	1,243	933.01	701.89
Revenue Growth	-20.44%	15.58%	52.97%	33.26%	32.93%	29.95%
Gross Profit	377.26	-163.43	778.36	215.61	-84.07	-160.24
Operating Income	-62.24	-657.77	218.08	-267.82	-536.2	-443.61
Net Income	-136.73	-713.41	235.24	-535.98	-703.49	-418.78
Earnings Per Share	-1.32	-7.13	2.34	-5.80	-8.03	-5.15
EPS Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total PMO Products	956.87	965.57	967.17	944.52	843.77	612.4
ELEVIDYS	441.99	898.73	820.79	200.36	-	-
Collaboration and Other	575.49	333.94	114.02	98.46	89.24	89.49
Revenue (Total)	1,974	2,198	1,902	1,243	933.01	701.89

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	788.49	939.65	1,355	1,676	1,989	2,116
Total Debt	1,062	1,040	1,330	1,379	1,617	1,138
Net Cash (Debt)	-273.92	-99.9	25.2	297.29	372.02	977.48
Net Cash Growth	-	-	-91.53%	-20.09%	-61.94%	12.91%
Net Cash Per Share	-2.64	-1.00	0.23	3.22	4.25	12.03

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	111.01	-205.48	-205.79	-500.99	-325.35	-443.17
Capital Expenditures	-29.16	-101.97	-136.96	-76.11	-30.82	-38.49
Free Cash Flow	81.85	-307.45	-342.74	-577.1	-356.17	-481.66
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	19.11%	-7.43%	40.92%	17.34%	-9.01%	-22.83%
Operating Margin	-3.15%	-29.92%	11.47%	-21.54%	-57.47%	-63.20%
Pretax Margin	-6.63%	-31.94%	13.71%	-41.83%	-73.95%	-59.69%
Profit Margin	-6.93%	-32.45%	12.37%	-43.11%	-75.40%	-59.66%
FCF Margin	4.15%	-13.99%	-18.02%	-46.41%	-38.17%	-68.62%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	49.37	-	-	-
Forward PE	40.05	90.12	15.47	-	-	-
PS Ratio	0.95	1.03	6.11	7.26	12.19	11.17